Collectively, this evidences a STAT3–AKT1–TP53 core network that integrates multiple GDM pathological mechanisms, including inflammation, oxidative stress, and insulin resistance, offering convergent targets for therapeutic intervention. This evidence concerns the gene STAT3 and gestational diabetes.